Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial - Summary - MDSpire
Advertisement
Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial
To evaluate the efficacy and safety of apitegromab in preserving lean mass in adults with overweight or obesity receiving incretin mimetic therapy, specifically targeting those undergoing such treatment.
Key Findings:
Apitegromab significantly reduced lean mass loss by preserving 1.9 kg of lean mass compared to placebo (P = 0.0014).
Total body weight loss was similar between groups, with lean mass loss representing 14.6% of weight loss with apitegromab versus 30.2% with placebo (P < 0.001).
At week 32, the difference in lean mass between apitegromab and placebo remained significant (P = 0.0480).
Safety profiles were similar between apitegromab and placebo, with gastrointestinal AEs being the most frequently reported.
Interpretation:
The results suggest that apitegromab may effectively preserve lean mass during weight loss induced by tirzepatide.
Limitations:
The study was limited to a specific population of adults with overweight or obesity, which may affect the generalizability of the findings.
The sample size may limit the robustness of the conclusions drawn from the study.
Conclusion:
Apitegromab shows potential in preserving lean mass during pharmacologic weight management, suggesting a need for further research to confirm these findings and their implications for clinical practice.
by Richard E. Pratley, Douglas Scott Denham, Rupal Trivedi, Elaine Watkins, Lisa Connery, Jennifer Barnes, Dongzi Yu, Janet Hong, Christopher Simard, Kimberly Umans, Lan Liu, Giridhar S. Tirucherai, Jing L. Marantz
